» Articles » PMID: 33392258

Differential Expression Profiles and Functional Prediction of Circular RNAs in Pediatric Dilated Cardiomyopathy

Overview
Specialty Biology
Date 2021 Jan 4
PMID 33392258
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Circular RNAs (circRNAs) have emerged as essential regulators and biomarkers in various diseases. To assess the different expression levels of circRNAs in pediatric dilated cardiomyopathy (PDCM) and explore their biological and mechanistic significance, we used RNA microarrays to identify differentially expressed circRNAs between three children diagnosed with PDCM and three healthy age-matched volunteers. The biological function of circRNAs was assessed with a circRNA-microRNA (miRNA)-mRNA interaction network constructed from Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes. Differentially expressed circRNAs were validated by quantitative real-time polymerase chain reaction (qRT-PCR) in 25 children with PDCM and 25 healthy volunteers. We identified 257 up-regulated (fold change ≤ 0.5, < 0.05) and 899 down-regulated (fold change ≥2, < 0.05) circRNAs in PDCM patients when compared to healthy volunteers. The qRT-PCR experiments confirmed has_circ_0067735 down-regulation (0.45-fold, < 0.001), has_circ_0070186 up-regulation (2.82-fold, < 0.001), and has_circ_0069972 down-regulation (0.50-fold, < 0.05). A functional analysis of these differentially expressed circRNAs suggests that they are associated with hypertrophy, remodeling, fibrosis, and autoimmunity. CircRNAs have been implicated in PDCM through largely unknown mechanisms. Here we report differentially expressed circRNAs in PDCM patients that may illuminate the mechanistic roles in the etiology of PDCM that could serve as non-invasive diagnostic biomarkers.

Citing Articles

CircRNA-mediated regulation of cardiovascular disease.

Cheng K, Wang S, Lan T, Mao Z, Xu Y, Shen Q Front Cardiovasc Med. 2024; 11:1411621.

PMID: 39660120 PMC: 11628502. DOI: 10.3389/fcvm.2024.1411621.


Circular RNAs: a small piece in the heart failure puzzle.

Eshraghi R, Shafie D, Raisi A, Goleij P, Mirzaei H Funct Integr Genomics. 2024; 24(3):102.

PMID: 38760573 DOI: 10.1007/s10142-024-01386-z.


Circular RNA Expression for Dilated Cardiomyopathy in Hearts and Pluripotent Stem Cell-Derived Cardiomyocytes.

Zhang Y, Huang G, Yuan Z, Zhang Y, Chang R Front Cell Dev Biol. 2022; 9:760515.

PMID: 34977015 PMC: 8719353. DOI: 10.3389/fcell.2021.760515.


Circulating circRNA as biomarkers for dilated cardiomyopathy etiology.

Costa M, Calderon-Dominguez M, Mangas A, Campuzano O, Sarquella-Brugada G, Ramos M J Mol Med (Berl). 2021; 99(12):1711-1725.

PMID: 34498126 PMC: 8599237. DOI: 10.1007/s00109-021-02119-6.

References
1.
Poller W, Kuhl U, Tschoepe C, Pauschinger M, Fechner H, Schultheiss H . Genome-environment interactions in the molecular pathogenesis of dilated cardiomyopathy. J Mol Med (Berl). 2005; 83(8):579-86. DOI: 10.1007/s00109-005-0664-2. View

2.
Fang Y . Circular RNAs as novel biomarkers with regulatory potency in human diseases. Future Sci OA. 2018; 4(7):FSO314. PMC: 6088266. DOI: 10.4155/fsoa-2018-0036. View

3.
Richardson P, McKenna W, Bristow M, Maisch B, MAUTNER B, OConnell J . Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation. 1996; 93(5):841-2. DOI: 10.1161/01.cir.93.5.841. View

4.
Devaux Y, Creemers E, Boon R, Werfel S, Thum T, Engelhardt S . Circular RNAs in heart failure. Eur J Heart Fail. 2017; 19(6):701-709. DOI: 10.1002/ejhf.801. View

5.
Everly M . Cardiac transplantation in the United States: an analysis of the UNOS registry. Clin Transpl. 2009; :35-43. View